The human-platelet aggregating factor in preparations of bovine plasma and bovine antihemophilic factor has been reported to be an activity of bovine antihemophilic factor. However, we show that activities of aggregating factor and antihemophilic factor are present in varying proportion in different preparations of antihemophilic factor. Aggregating factor activity is more stable on storage than is antihemophilic factor activity and can be selectively adsorbed by human platelets. Further, antihemophilic factor activity free of aggregating activity was eluted from DEAE-Sephadex. The factors were also separated during agarose chromatography in 0.25 M CaCl2, which yields a small-molecular-weight moiety with antihemophilic factor activity; aggregating factor activity continued to elute in the void volume. Thus, aggregating factor activity is clearly separable from antihemophilic factor activity. The usual physiologic platelet-aggregating reactions require fresh platelets. Fresh, aged, and sonicated platelets, but not platelets that have been frozen and thawed, react with aggregating factor, indicating that the platelet "receptor sites" for the aggregating factor are unusually stable.
Aggregation of blood platelets is induced by several physiologic substances. Divalent cation is needed for these substances to be effective, and fibrinogen is an essential cofactor for several platelet-aggregating reactions (1, 2) . Another component of the clotting system, antihemophilic factor (AHF, factor VIII), has been suggested as being concerned with platelet function (3) . There is considerable species variation in the response of platelets to various aggregating agents (4, 5) . In the platelet-aggregating reaction that occurs when human platelets are mixed with bovine plasma without added cation, the aggregating activity appears to be concentrated in bovine-plasma fractions rich in fibrinogen and AHF. This reaction may further elucidate the role of certain plasma factors, e.g., fibrinogen, AHF, and "von Willebrand factor" (vWF, "vascular" factor), in the hemostatic function of platelets.
The bovine-aggregating factor for human platelets was recognized when concentrates of animal AHF were first used for treatment of human hemophilia (6) . Thrombocytopenia occurred promptly. The aggregating agent was believed to be a heterologous antibody (6) . After the demonstration that fibrinogen is an essential cofactor for several types of platelet aggregation, it was suggested that the fibrinogen content or thrombocyte-agglutinating activity (TAg) of preparations of animal AHF was responsible for their platelet-aggregating effect (7, 8) . With separation of fibrinogen from AHF by gel chromatography, the aggregating agent was found to elute with the AHF activity. These findings, along with other characteristics of the aggregating factor (7, 8) , led to the suggestion that the AHF activity and the platelet-aggregating activity were identical (9, 10) .
The studies reported here re-examine the association of bovine platelet-aggregating factor (PAF) and AHF. Separation of these two activities in bovine plasma and plasma fractions by several procedures is reported. Recent data on the complex nature of plasma AHF, in combination with the data reported here, indicate that PAF activity is distinct from the isolated AHF activity, but is closely associated with and could even be a function of a large carrier protein which binds a smaller AHF moiety (11) .
MATERIALS AND METHODS
Bovine Plasma was obtained from blood collected in 3.2% trisodium citrate during slaughter of adult animals. The blood was immediately stored on ice and transported to the laboratory, where platelet-poor plasma was promptly prepared and fractionated or frozen at -20°. Samples were thawed at 370 immediately before use.
Concentrates of Bovine-Plasma AHF were of three types: (1) "AHG (bovine)," obtained from S. Maw Son and Sons, Ltd., England; (2) glycine-precipitated (Wagner method) (12) , prepared to our specifications by Hyland Laboratories, Los Angeles; (3) a highly purified concentrate prepared by a threestep procedure consisting of (a) plasma concentration by dialysis against polyethylene glycol, (b) precipitation at 00, and (c) agarose chromatography (13 previously. These concentrates were pooled in siliconized glass tubes and centrifuged at 1000 X g for 10 min. The platelets were washed three times in a solution of 3.2% trisodium citrate diluted 1:20 with saline. For some experiments, several platelet buttons were frozen quickly in a dry ice-acetone bath and then stored at -20°for 24 hr before use. These suspensions were designated "freeze-thaw" platelets.
Adsorption of Bovine Plasma Preparations with Human Platelet Suspensions. When gel-filtered platelet suspensions were used, platelet buttons were prepared by centrifugation of 2 ml of suspension as it came from the column (1000 X g, 3 min). The supernatant was discarded, and the platelets were suspended in 5 ml of dilute preparations of bovine AHF. The suspension was gently agitated (5 min, 25°) and then centrifuged as above; 0.3 ml of the supernatant was removed for assays and the remainder was added to another platelet button. This procedure was repeated up to six times. Because of of the small number of platelets available in these suspensions, dilute samples of AHF concentrates (0.02-0.1 bovine AHF units per ml) were used. The adsorption procedure was the same with sonicated platelets, except that after sonication the buttons were prepared by ultracentrifugation (20,000 X g, 20 min, 4°) and were washed once before they were used for adsorption, and only 1 ml of dilute AHF preparation was added.
When washed platelet suspensions were used, the number of platelets and the concentration of AHF in each adsorption step were much greater than in the adsorption studies with gelfiltered platelets. Each platelet button (1000 X 9, 10 min) contained the platelets from 1 unit of blood. AHF solutions used contained about 1 unit/ml. The procedure otherwise was similar to that described above.
Chromatography. Both ion-exchange and agarose column chromatography were used to study the AHF preparations. Assay Methods. AHF in bovine-plasma preparations was assayed by a modification of the partial thromboplastin time assay (17) with a kaolin activated system and substrate plasma from the Chapel Hill colony of hemophilia A dogs. A further modification was used when fractions were obtained in the Tris-calcium dissociation buffer (18) . One unit of AHF activity is defined as that amount in 1 ml of normal bovine plasma. The identity test for AHF consisted of a modified neutralization procedure (19) in which plasma from a human patient with hemophilia A with a high titer of circulating anticoagulant, an antibody against AHF, was incubated with the test material, PAF activity in bovine-plasma preparations was assayed by a modification of the macroscopic aggregating test (20) . The test consisted of 0.2 ml of gel-filtered platelet suspension Table 1 . The relative concentrations of the two activities were arbitrarily considered as 1:1 in normal bovine plasma. In the AHF concentrate of high purity (purified 2000-4000 times in relation to plasma AHF and plasma protein), AHF was present in a relatively greater amount than PAF. The converse was true for the two preparations of intermediate purity, with the relative concentration of PAF being greater. PAF was more stable than AHF when plasma or concentrate was stored at room temperature.
Selective Adsorption of PAF Activity from Bovine Plasma and AHF Concentrates. PAF could be selectively removed from the preparations by adsorption with human platelets (Table 2) . However, the adsorbed preparations, free of PAF, still contained AHF. All types of suspensions used were effective in removing PAF except for the freeze-thaw type. The platelet suspensions were used from 2-96 hr after collection of blood. They were effective as an adsorbing agent regardless of time of storage. Each of the preparations of bovine-plasma AHF listed in Table 1 t Not measured. tion step until, finally, it could not be detected. In one experimnent, all the PAF was removed by a single adsorption procedure, but a very dilute bovine preparation with a concentrated platelet suspension was used.
Quantitation of AHF after adsorption with platelets gave variable results ( Table 2 ) apparently because of interfering substances in the bioassay preparation resulting from exposure of the plasma and concentrates to large numbers of platelets. However, incubation with human antibody against AHF resulted in prolongation of assay clotting times, verifying the presence of AHF.
Retention of PAF Activity After Neutralization of AHF Activity. After incubation of PAF-containing preparations with a specific AHF-inhibitinig antibody in human hemophilic plasma, PAF activity was retained while AHF activity was lost. In two experiments, one with plasma and the other with glycine-precipitated preparation, AHF activity was completely lost after 30 min of incubation, while the titer of PAF was unchanged. Others have made similar observations (8, 10) .
Separation of PAF from Bovine AHF by Chromatography. The aggregating factor and its relationsip to bovine AHF were better characterized in. three sets of chromatographic experiments. DEAE-Sephadex chromatography was first used (Fig. 1) . The gradient between 0.2 and 0.5 M Tris -HCl eluted fractions with a broad peak of activity containing both AHF and PAF and a later peak of AHF activity with little or no PAF.
In a second group of experiments, agarose column chromatography was used to compare AHF elution behavior before and after removal of PAF from plasma preparations by adsorption by human platelets. Fig. 2A shows typical results when unadsorbed bovine plasma is chromatographed on agarose. AHF and the PAF appear in the fractions in or close to the void volume and, therefore, are of very high molecular weight. Fig. 2B shows the results of chromatography of a sample of bovine plasma from which the PAF activity had been removed by adsorption with washed platelets, comparable to the adsorbed sample (washed, aged) of Table 2 . Again, AHF activity was excluded from the gel, and therefore was of large size, even though PAF did not accompany it. In the third group of experiments, AHF in highly purified preparations of bovine AHF was chromatographed in 0.25 M CaCl2, a concentration that dissociates canine AHF into a small active molecule and a large inactive molecule (i8). Results of an illustrative experiment are shown in Fig. 3 . Dissociated AHF eluted from the column in late fractions, while PAF was found in the void volume.
DISCUSSION
In this paper we show by several procedures that the AHF activity and the PAF activity for human platelets of bovine plasma can be separated. Previous work has emphasized the similarities of the AHF and the bovine PAF (9, 10). These studies pointed out the comparable lability of the two factors when exposed to heat (56i60o) and during clotting of blood and the similar behavior of the two activities on agarose gel chromatography, both eluting as large-molecular-weight entities in the void volume. The unequal partition of PAF and AHF activities in different preparations of bovine plasma and plasma-concentrates first suggested to us that they might be separable entities. There is a higher ratio of PAF to AHF in all of the bovine-plasma concentrates except for the fresh, highly purified preparation (Table 1) . These findings could in part be due to the greater lability of AHF, noted both in stored plasma and in stored highly purified concentrate. The greater concentration of AHF than PAF in the bovine AHF preparation of high purity does suggest that the two activities might be separated by appropriate procedures. However, present methods for purification of AHF are inadequate for this purpose, and it is impossible to prepare nonthrombocytopenic bovine AHF concentrates for therapeutic use.
All the measurable PAF can be removed from bovineplasma preparations by adsorption with human platelets, with AHF activity remaining ( Table 2 ). The effectiveness of the adsorption procedure was related to the concentration of the platelets and the number of times the adsorption procedure was repeated, as well as to the concentration of PAF in the preparations. Calculations of the number of human platelets required to remove the aggregating activity from the equivalent of 1 ml of bovine plasma gave a very large value, platelets normally present in that volume of plasma, either human or bovine. Platelets are very labile cells, and in many of the physiological aggregating reactions, e.g., with ADP and thrombin, they rapidly lose their ability to aggregate with ageing (21); intact platelets are required. For the PAF reaction, in contrast (Table 2 h "receptor sites" on the platelets appear to be relatively stable, and fragmented platelets retain their ability to react. Only in freeze-thaw platelets was there loss of aggregating and adsorbing capacity.
Since variable results were obtained in several AHF bioassays of bovine preparations after they had been exposed to such large numbers of platelets, several control experiments were done to verify that the clotting activity after adsorption was not due solely to some platelet derivative or other contaminant. Neutralization tests with a human antibody against AHF demonstrated that AHF was present after adsorption.
Gel-filtered human platelets from a hemophilic donor, devoid of AHF, were used in one experiment ( Table 2 ) to show that the AHF present after adsorption was not of human origin. Again, PAF was selectively removed and AHF activity remained. Finally, agarose-gel chromatography of the material after adsorption showed that AHF freed of PAF continued to behave as before, eluting in the void volume (Fig. 2B) . These experiments would indicate that the AHF that remained after platelet adsorption was not greatly altered, if at all, in regard to clotting activity, reactivity with a specific antibody, and elution behavior during gel chromatography.
The second approach to separation of AHF and PAF was neutralization of AHF activity with inhibitor antibody. PAF activity was not affected by this procedure, which yields PAF without AHF (8, 10) . In these studies, as in the platelet adsorption experiments, one of the activities was retained at the expense of the other.
A last set of experiments with ion-exchange and agarose chromatography was aimed at separation of PAF and AHF without loss of either of the activities. A requirement for separation of the two activities by chromatography was high ionic strength in the solution. With the DEAESephadex column (Fig. 1) , PAF and AHF appeared together in the midportion of the gradient. Unlike AHF, PAF appeared to be completely eluted at 0.2-0.5 M Tris -HCl. At higher ionic strength only AHF appeared. If one assumes that an AHF complex is dissociated at these high ionic strengths, as has been shown with canine and human AHF (11, 18, 22, 23) , then the AHF associated with PAF in the earlier parts of the gradient is in the large-molecular-weight, complexed form, while in the latter part of the gradient, the PAF-free AHF is in the low-molecular-weight, dissociated form.
With agarose-gel chromatography, AHF was dissociated with high concentrations of CaCl2. After dissociation, PAF eluted in the void volume, while AHF, free of PAF activity, was eluted later. These data differ from those of Donati et al. (9) ,. probably because of different experimental conditions.
A common view is that the antihemophilic factor is of extremely large molecular weight, perhaps up to two million, and is possibly made up of repeating identical subunits (22) (23) (24) (25) . Several of us (11, 18) have presented evidence that AHF activity is associated with a small-molecular-weight entity, as judged by chromatography, which is complexed with a large carrier protein. The usual physicochemical attributes of AHF as found in plasma are due to the complex between carrier and active small subunit.
Perhaps this AHF complex is associated with another plasma factor, the "von Willebrand factor," which is needed for platelet adhesion and normal hemostasis. Bouma et al. Fig. 4 summarizes some of our speculations about the molecular identity or nonidentity of AHF carrier protein, bovine PAF and "von Willebrand factor." While the postulation of a single macromolecule with multiple functions is attractive on a biological economy basis, our platelet adsorption data taken at face value make this unlikely. The three-macromolecules hypothesis, one macromolecule-for each separate function, is also compatible with the data.
Two of the functions, PAF and "von Willebrand factor," are expressed by reacting with platelets. If they were molecularly identical, the "'packaging" possibilities would be greatly simplified. There could be one molecule with two functional sites, one with AHF binding capacity and another with platelet binding capacity. Alternatively there could be two separate molecules, one for each of these sites.
